Humana ยท HUM

Humana's raised guidance still allows a far deeper fourth-quarter loss than last year's

Humana lifted its adjusted earnings floor for the year on 6 November, yet its first half was only level with last year's and the whole of this year's decline falls after June.

4 min read Published on

Published by

Inve Content team

Humana stock page โ†’ More news from Nov 12, 2026

A physician in a white coat consulting with an older patient in a sunlit outpatient medical clinic.
Illustration Photo: Inve Research Desk

Humana raised its earnings guidance for the year on 6 November and now expects adjusted earnings of at least $9.50 a share, up from at least $9. "We have just one headline today, and that is that we are in a good place," said James Rechtin, the president and chief executive. The raise is small next to what the year has already earned: $17.17 a share of adjusted earnings in the first nine months. Finishing at the new floor would mean an adjusted loss in the fourth quarter of as much as $7.67 a share, calculated from the reported figures, close to double the loss in the same quarter a year earlier.

That gap says more about where Humana's profit comes from than the raise does. Humana runs health plans for people on Medicare and Medicaid, collecting premiums and paying its members' doctor, hospital and drug bills out of them, and its profit is earned early in the year. Celeste Mellet, the chief financial officer, said pharmacy bills take a larger share of benefit costs as the months go by. In the filed results, the fourth quarter has lost money at the operating level in each of the last three years, each time after three profitable quarters.

Humana's operating profit comes early; its fourth quarter lost money in every year from 2023 to 2025

$m

  1. Q4 2024 -543
  2. Q1 2025 $2014m
  3. Q2 2025 $1098m
  4. Q3 2025 $400m
  5. Q4 2025 -808
  6. Q1 2026 $1754m
  7. Q2 2026 $1360m
  8. Q3 2026 $75m
Operating profit as filed, quarters to September 2026.

That seasonal pattern is familiar, and this year management warned in February that the Stars headwind would make the second half worse than last year's. The figures show how far. By our arithmetic from the reported nine-month and quarterly figures, adjusted earnings per share in the first half were essentially unchanged from a year earlier, a cent apart, so the whole decline the company guides for this year comes after June. In the September 2026 quarter Humana made an adjusted loss per share, against a profit a year earlier, and the floor leaves room for a fourth quarter worse than last year's. The company's release puts the year's decline down to the Star Ratings headwind, net of the steps taken to offset it: Humana's lower star ratings cut the quality bonus payments it receives from the government this year.

The first half was level with last year; this year's decline all lands after June

$ a share

  1. First half 2025 17.86
  2. First half 2026 17.87
  3. Third quarter 2025 $3.24
  4. Third quarter 2026 -0.70
  5. Fourth quarter 2025 -3.96
  6. Fourth quarter 2026, guidance floor -7.67
Adjusted EPS. First-half and fourth-quarter values are Inve's calculation from the reported nine-month and full-year results; the 2026 fourth quarter is the largest loss the guidance of at least $9.50 allows. Share counts differ between quarters, so the halves are approximate.

The quarter was not weak on every measure. The share of insurance premiums paid out in benefits came in better than management had guided. But revenue grew by about a quarter from a year earlier while operating profit shrank. The reported, or GAAP, results point the other way, showing a pretax profit for the quarter rather than a loss. Most of the difference is a non-cash gain from revaluing the put and call options in Humana's primary-care clinic joint ventures with Welsh, Carson, Anderson & Stowe. A new venture with BlackRock has replaced those joint ventures, and the reversal of the put liability itself is in the full-year guidance, not this quarter. The company describes such fair-value adjustments as unrelated to its core business.

Should the floor be read as the company's own expectation for the fourth quarter? The comparable points suggest it can be. At the same stage last year, management guided to approximately $17 a share for that year, a figure that also implied a heavy fourth-quarter loss, and the year closed slightly above it. At the same stage two years earlier, with the guide worded as a floor, as it is now, the year came in line with the company's initial guidance for that year, Rechtin said the following February. A floor still leaves room for a smaller loss.

Management's case that the business is moving ahead of plan rests on next year and the one after. Mellet said the bids Humana has priced for next year assume medical and drug costs rise faster than this year, and that margins in its individual Medicare Advantage plans should improve materially, to a level "well into the profitability range, even reflecting the Stars headwind for next year". Rechtin said the company now expects its membership to grow next year, though enrolment is still in its early days. Its latest star ratings, which set bonus payments further out, came in high, and he said the one-time benefit they bring will be so large that "we will not be able to productively invest all of it". Rechtin said the company would update its progress against its investor-day targets at an investor update on 10 December.

Humana stock page โ†’

The record: full financial tables

Financials

Income statement, last 8 quarters

$ million; YoY and margin in %
Quarter endSalesYoYOperating profitOp. marginPBTNet profit
Sep 202641,155+26.1%750.2%216162
Jun 202640,867+26.2%1,3603.3%952694
Mar 202639,648+23.5%1,7544.4%1,5951,186
Dec 202532,515+11.3%โˆ’808โˆ’2.5%โˆ’1,011โˆ’796
Sep 202532,649+11.1%4001.2%134195
Jun 202532,388+9.6%1,0983.4%741545
Mar 202532,112+8.4%2,0146.3%1,6911,244
Dec 202429,213+10.4%โˆ’543โˆ’1.9%โˆ’862โˆ’693

Balance sheet

$ million
As ofEquityDebtCashInvestmentsFixed assetsTotal assets
Sep 202618,82512,5046,93518,1742,07057,285
Jun 202619,21314,2476,89316,9782,09857,196
Mar 202618,58013,9934,95117,0142,17055,280
Dec 202517,65712,3694,20015,7032,23148,909

Cash flow

$ million
Year endOperatingInvestingFinancingFree cash flow
Dec 20259212,273โˆ’1,215375
Dec 20242,966โˆ’2,952โˆ’2,4872,391
Dec 20233,981โˆ’3,492โˆ’8562,977
Dec 20224,587โˆ’1,006โˆ’1,9143,450